BACKGROUND AND AIM: The cytokeratin (CK)7(-) /CK20(+) immunoprofile is characteristic of colorectal carcinoma (CRC), although CK7(+) or CK20(-) phenotypes are occasionally encountered, particularly in histologically variant CRCs. We analyzed CK7/CK20 profiles in variant CRCs in association with clinicopathologic parameters and prognosis. METHODS: CK expression in well- and moderately differentiated adenocarcinoma (WMDA) (n = 63), poorly differentiated adenocarcinoma (PDA) (n = 91), mucinous adenocarcinoma (MUA) (n = 81), signet-ring cell carcinoma (SRCC) (n = 15), undifferentiated carcinoma (UDC) (n = 12), and adenosquamous carcinoma (n = 2) was analyzed using immunohistochemistry. Cut-off scores were set at 1% for CK7 and 25% for CK20 using the receiver operating characteristic curve analysis of PDA. Association between CK20(-) and better prognosis in PDA was validated in the second cohort (n = 66). RESULTS: CK7/CK20 immunoprofiling revealed a predominant CK7(-) /CK20(+) profile in WMDA, MUA, and SRCC, while the majority of UDC was characterized by a CK7(-) /CK20(-) profile. The CK7/CK20 profile in PDA was variable. Contingency table analysis revealed that CK expression was not significantly associated with any clinicopathologic parameters in WMDA, PDA, and MUA. However, survival analysis demonstrated that CK20(-) was significantly associated with better prognosis in PDA. Although CK20(-) was significantly associated with mismatch repair deficiency in PDA, it was an independent prognostic factor in multivariate analysis. Finally, we confirmed that CK20 status, determined using a 25% cut-off score, was a significant prognostic parameter in the second PDA cohort. CONCLUSIONS: CK20 status may be used as a prognostic predictor of PDA.
BACKGROUND AND AIM: The cytokeratin (CK)7(-) /CK20(+) immunoprofile is characteristic of colorectal carcinoma (CRC), although CK7(+) or CK20(-) phenotypes are occasionally encountered, particularly in histologically variant CRCs. We analyzed CK7/CK20 profiles in variant CRCs in association with clinicopathologic parameters and prognosis. METHODS: CK expression in well- and moderately differentiated adenocarcinoma (WMDA) (n = 63), poorly differentiated adenocarcinoma (PDA) (n = 91), mucinous adenocarcinoma (MUA) (n = 81), signet-ring cell carcinoma (SRCC) (n = 15), undifferentiated carcinoma (UDC) (n = 12), and adenosquamous carcinoma (n = 2) was analyzed using immunohistochemistry. Cut-off scores were set at 1% for CK7 and 25% for CK20 using the receiver operating characteristic curve analysis of PDA. Association between CK20(-) and better prognosis in PDA was validated in the second cohort (n = 66). RESULTS:CK7/CK20 immunoprofiling revealed a predominant CK7(-) /CK20(+) profile in WMDA, MUA, and SRCC, while the majority of UDC was characterized by a CK7(-) /CK20(-) profile. The CK7/CK20 profile in PDA was variable. Contingency table analysis revealed that CK expression was not significantly associated with any clinicopathologic parameters in WMDA, PDA, and MUA. However, survival analysis demonstrated that CK20(-) was significantly associated with better prognosis in PDA. Although CK20(-) was significantly associated with mismatch repair deficiency in PDA, it was an independent prognostic factor in multivariate analysis. Finally, we confirmed that CK20 status, determined using a 25% cut-off score, was a significant prognostic parameter in the second PDA cohort. CONCLUSIONS:CK20 status may be used as a prognostic predictor of PDA.
Authors: Jerzy Lasota; Małgorzata Chłopek; Jennifer Lamoureux; Jason Christiansen; Artur Kowalik; Bartosz Wasąg; Anna Felisiak-Gołąbek; Abbas Agaimy; Wojciech Biernat; Vincenzo Canzonieri; Giovanni Centonze; Ewa Chmielik; Ondrej Daum; Magdalena Dubová; Ireneusz Dziuba; Sebastian Goertz; Stanisław Góźdź; Anna Guttmejer-Nasierowska; Caj Haglund; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Paweł Kita; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Ari Ristimäki; Janusz Ryś; Blażej Szostak; Joanna Szpor; Justyna Szumiło; Leszek Teresiński; Piotr Waloszczyk; Jarosław Wejman; Wojciech Wesołowski; Markku Miettinen Journal: Am J Surg Pathol Date: 2020-02 Impact factor: 6.298
Authors: Jerzy Lasota; Małgorzata Chłopek; Bartosz Wasąg; Artur Kowalik; Jason Christiansen; Jennifer Lamoureux; Alina Kuźniacka; Anna Felisiak-Gołąbek; Yalan Liu; Tiffany Ashley R Reyes; Rishabh Saha; Abbas Agaimy; Kristyna Behenska; Wojciech Biernat; Laura Cattaneo; Giovanni Centonze; Ondrej Daum; Magdalena Daumova; Paweł Domagała; Ireneusz Dziuba; Carol E Geppert; Stanisław Góźdź; Anna Nasierowska-Guttmejer; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Janusz Ryś; Piotr Waloszczyk; Jaroslaw Wejman; Markku Miettinen Journal: Am J Surg Pathol Date: 2020-09 Impact factor: 6.298